arrow
Back
E

Edward M. Sellers

university of toronto

85H-index
519Paper Count
3.8WCitation Count
Published Papers 85
Publication Date
errShare
errSave
Identification of Optimal Measures of Human Abuse Potential A Post Hoc Assessment of 19 Studies
err2020-10-21
err1
PREAI
errShram, Megan J.; Levy-Cooperman, Naama; Ratcliffe, Sian; Mills, Catherine; Bartlett, Cynthia; Chen, Nancy; Setnik, Beatrice; Sellers, Edward M.; Schoedel, Kerri A.
errShare
errSave
Opioids: The Painful Public Health Reality
err2018-05-16
err8
errOAAI
errTyndale, Rachel F.; Sellers, Edward M.
errShare
errSave
errShare
errSave
Evaluation of human abuse liability of JZP-110
err2017-02-01
err0
PREAI
errCarter, Lawrence P.; Sellers, Edward; Henningfield, Jack; Wang, Grace; Lu, Yuan; Kelsh, Debra; Vince, Bradley
errShare
errSave
Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist
err2016-12-01
err29
errOAAI
errLevy-Cooperman, N.; McIntyre, G.; Bonifacio, L.; McDonnell, M.; Davenport, J. M.; Covington, P. S.; Dove, L. S.; Sellers, E. M.
errShare
errSave
errShare
errSave
The Effect of an Abuse-Deterrent Opioid Formulation (OxyContin) on Opioid Abuse-Related Outcomes in the Postmarketing Setting
err2016-06-22
err70
errOAAI
errCoplan, P. M.; Chilcoat, H. D.; Butler, S. F.; Sellers, E. M.; Kadakia, A.; Harikrishnan, V.; Haddox, J. D.; Dart, R. C.
errShare
errSave
Assessment of the Abuse Liability of a Dual Orexin Receptor Antagonist: A Crossover Study of Almorexant and Zolpidem in Recreational Drug Users
err2014-03-14
err13
PREAI
errCruz, Hans G.; Hoever, Petra; Chakraborty, Bijan; Schoedel, Kerri; Sellers, Edward M.; Dingemanse, Jasper
errShare
errSave
errShare
errSave
Update on tamper-resistant drug formulations
err2013-06-01
err49
PREAI
errRomach, M. K.; Schoedel, K. A.; Sellers, E. M.
errShare
errSave
Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations
errPAIN
IF5.5
err2012-12-01
err59
errOAAI
errComer, Sandra D.; Zacny, James P.; Dworkin, Robert H.; Turk, Dennis C.; Bigelow, George E.; Foltin, Richard W.; Jasinski, Donald R.; Sellers, Edward M.; Adams, Edgar H.; Balster, Robert; Burke, Laurie B.; Cerny, Igor; Colucci, Robert D.; Cone, Edward; Cowan, Penney; Farrar, John T.; Haddox, J. David; Haythornthwaite, Jennifer A.; Hertz, Sharon; Jay, Gary W.; Johanson, Chris-Ellyn; Junor, Roderick; Katz, Nathaniel P.; Klein, Michael; Kopecky, Ernest A.; Leiderman, Deborah B.; McDermott, Michael P.; O'Brien, Charles; O'Connor, Alec B.; Palmer, Pamela P.; Raja, Srinivasa N.; Rappaport, Bob A.; Rauschkolb, Christine; Rowbotham, Michael C.; Sampaio, Cristina; Setnik, Beatrice; Sokolowska, Marta; Stauffer, Joseph W.; Walsh, Sharon L.
errShare
errSave
Differences in the In Vitro and In Vivo Pharmacokinetic Profiles of Once-Daily Modified-Release Methylphenidate Formulations in Canada: Examination of Current Bioequivalence Criteria
err2012-05-01
err17
PREAI
errShram, Megan J.; Quinn, Anne Marie; Chen, Nancy; Faulknor, Janice; Luong, Doanh; Sellers, Edward M.; Endrenyi, Laszlo
errShare
errSave
Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5-HT2C) Receptor Agonist, in Recreational Polydrug Users
err2011-03-16
err59
PREAI
errShram, M. J.; Schoedel, K. A.; Bartlett, C.; Shazer, R. L.; Anderson, C. M.; Sellers, E. M.
errShare
errSave
The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential
err2010-12-01
err10
PREAI
errMansbach, Robert S.; Schoedel, Kerri A.; Kittrelle, Jeffrey P.; Sellers, Edward M.
errShare
errSave
Oral ketamine as a positive control in human abuse potential studies
err2010-11-24
err23
PREAI
errShram, M. J.; Sellers, E. M.; Romach, M. K.
errShare
errSave